Participating Companies

Abliva Ab
[ABLI-SE]
Focused on rare and severe primary mitochondrial diseases (PMD). KL1333, a NAD+ regulator, to accelerate into pivotal studies in 2H21 based on positive FDA feedback; initial results from Ph1b in PMD patients exp. in 1Q21. NV354, an energy replacement therapy for Leigh Syndrome, in IND-enabling studies. [more information]

AcelRx Pharmaceuticals, Inc.
[ACRX]
US$273 MM MCap
Launched DSUVIA (sufentanil sublingual tablet 30 mcg) in the US in 2019 for acute pain severe enough to require opioid analgesic (adult patients in certified medically supervised healthcare settings). Also developing Zalviso (Ph 3 completed) in the US as an innovative patient-controlled analgesia system for moderate-to-severe acute pain in medically supervised settings. [more information]

Achilles Therapeutics
cNeT (clonal neoantigen) process builds on TILs, combined with ability to identify pt-specific clonal neoantigens and generate personalized T-cell therapies. Sep19 GBP100 million Series B w/ RA, Syncona, Forbion, Invus, Perceptive + Redmile. [more information]

Adrenomed AG
Precision medicine, cardiovascular and Sepsis, Adrecizumab Ph 2, biomarker-guided, monoclonal antibody for septic shock; final data released late November:
Early application of Adrecizumab leads to a rapid and statistically significant improvement of fluid balance, systemic organ function and > 50% relative reduction of all cause mortality after 28 days and 90 days compared to placebo on top of SoC.
[more information]

Affibody
Proprietary Affibody® molecules and Albumod platforms. Lead candidate is an IL-17 with positive Ph2 52wk data in psoriasis and Ph2 IND for lead indication uveitis will be filed in Q1 2021. In addition, the company has an ongoing relationship with Inmagene in China. Backed by Investor AB. [more information]

Affimed N.V.
[AFMD]
US$657 MM MCap
NK cell engager AFM13 (CD30/CD16A) to enter a Phase 2 registration study in CD30-positive peripheral T cell lymphoma and an investigator-sponsored study by MDACC of AFM13 combined with allogeneic NK cells in relapsed/refractory CD30-positive lymphoma. [more information]

AM-Pharma B.V.
Results from Ph 2 in 300+ pts demonstrated improvement of 40%+ OS in recAP group. Initiated Ph 3 in Q4 2020; TL safety & futility analysis on first 400 pts exp YE2021. Expects to complete tgt enrollment & announce primary endpoint data of 28-day all-cause mortality in 2023. [more information]

Amarin Corporation
[AMRN]
US$2,908 MM MCap
Commercializing Vascepa, the first and only pure EPA omega-3 fatty acid approved to lower triglyceride levels in adults. Presented (+) data from REDUCE-IT CV Outcomes trial at AHA. First 9mo rev’s of 2020 ~$450M. [more information]

Apexigen
CD40 agonist mAb; 170+ pts dosed (mono & combi settings). 7 ongoing Ph 2s, undisclosed ocular disease program in Ph 3. AACR: Ph 1b data (w/Parker Inst); collabs w/BMY, MDACC, Yale, et al [more information]

Aptorum Group
[APM]
US$117 MM MCap
Aptorum is Hong Kong based, US listed company (Mcap $100m) focused on generating late stage clinical candidates by developing already approved drugs for new orphan indications, as well as infectious diseases.
Pipeline –
• SACT-1 for Neuroblastoma – ph2/3 trial planned for 2H’20
• SACT-COV19 – COVID-19 treatment - preclinical [more information]

Arcellx
Clinical stage development of Antigen Receptor Complex T-cells (ARC-T) that are readily silenced, activated and reprogrammed in vivo by administration of a tumor-targeting antigen protein called a sparX. Backed by NEA, Novo, SR One, Takeda, Solasta, Quan, Clough, Mirae, JVC and LG. [more information]

AsclepiX Therapeutics
AXT107 demonstrated efficacy and durability in rabbit and mouse models that is superior to standard of care Eylea. [more information]

AxoGen
[AXGN]
US$745 MM MCap
Axogen is a pioneer in the regenerative medicine market, with a product portfolio for peripheral nerve repair. [more information]

Bellus Health
[BLU]
US$265 MM MCap
BELLUS' lead product candidate, BLU-5937, is being developed for the treatment of chronic cough (Phase II announced July 2020) and chronic pruritus (Phase II planned to begin 1H20). [more information]

BerGenBio
[BGBIO:OS]
NKr3,076 MM MCap
Developing first-in-class selective Axl kinase inhibitors for liquid and solid cancers, lead candidate is bemcentinib (BGB324) in four company-sponsored trials. [more information]

Biohaven Pharmaceuticals, Inc
[BHVN]
US$5,261 MM MCap
NURTEC® ODT approved in 1Q20. Topline results expected 1Q20 in Ph 3 study of troriluzole for migraine prevention. Topline results expected 2Q20 in Ph 2/3 study of troriluzole for OCD. ~$600M total in cash on hand, including recent $282.3M raise to support NURTEC ODT launch. [more information]

BioShin
Newly incorporated (Nov 2018), wholly owned subsidiary of Biohaven Pharmaceuticals. Shanghai-based, led by ex-BMY exec and Biohaven’s Chief of Corp Strategy & BD, Donnie McGrath, Bioshin aims to develop and commercialize Biohaven’s late-stage migraine and neurology portfolio in China and other APAC markets. [more information]

BioXcel Therapeutics, Inc.
[BTAI]
US$1,252 MM MCap
BXCL501 (sublingual dexmedetomidine): Met primary, key secondary and exploratory endpoints in two pivotal Phase 3 trials for the for the acute treatment of agitation in patients with schizophrenia (SERENITY I) and bipolar disorder (SERENITY II). Phase 1b/2 trial (TRANQUILITY) ongoing for the acute treatment of agitation associated with geriatric dementia. [more information]

CalciMedica
Focused on CRAC channel for the treatment of acute and severe inflammatory diseases. CalciMedica’s lead compound Auxora has delivered promising Phase 2 results in severe COVID-19 pneumonia and acute pancreatitis. A Phase 2/3 clinical trial of Auxora in up to 400 patients with severe COVID-19 pneumonia is ongoing, and a Phase 2b trial of Auxora in patients with acute pancreatitis and a dose escalating phase 2 study in ventilated ARDS patients with COVID-19 and other pneumonia are expected to commence soon. [more information]

CASI Pharmaceuticals Inc.
[CASI]
US$441 MM MCap
Co-commercial asset CNCT-19/CD19 CAR-T (partnered w/ Juventas): ongoing Ph 1 trials in B-NHL and B-ALL, exp to initiate registration trials by YE 2020. Exp to initiate Ph 1 study for CID-103 (anti-CD38 mAb) in EU in Q1 2021. [more information]

Catalyst Pharmaceuticals, Inc.
[CPRX]
US$376 MM MCap
Firdapse approved for Lambert-Eaton Myasthenic Syndrome (LEMS) with 3Q20 revenue of $29.2M. Top SMA Type 3 proof of concept trial expected to readout by YE 2020. Firdapse long acting formulation development continues. Studies for 2 additional neuromuscular indications are expected to commence by YE 2020. [more information]

Celularity
Productize allogeneic cells and tissues derived from the postpartum placenta and have the ability to augment immunity and longevity by amplifying the body's ability to fight disease, heal and regenerate itself, enabling patients to begin treatment more quickly, resulting in a better medical outcome. [more information]

Clerio Vision, Inc.
Novel ophthalmic technology to treat refractive error addressing multi-billion markets in contact lenses (presbyopia) and corneal vision correction (non surgical flapless laser solution). Based on Nobel Prize winning femto-second laser technology developed by Bausch & Lomb and the University of Rochester. [more information]

CureVac AG
[CVAC]
US$17,571 MM MCap
German mRNA company with a diversified pipeline; Ph 2a trial ongoing with COVID-19 vaccine candidate, CVnCoV. Global Ph 2/3 trial enrolling approx. 36,500 participants with results expected 1Q21. Three other programs in Ph 1: CV8102 (cutaneous melanoma, adenoidcystic carcinoma, squamous cell cancer of skin, head & neck), CV9202 (NSCLC) and CV7202 (Rabies). mRNA-based antibody delivery deal with Genmab (Dec'19). Other strategic partnerships include GSK and CRISPR Tx. [more information]

Enko Chem
The company specializes in discovering small molecules for the control of agriculturally important pests, herbs and fungus that damage the crop by producing toxic compounds and decrease the quality of the crop, enabling farmers to maximize resource efficiency and eliminate or minimize product hazards to create durable programs for agriculture productivity. [more information]

ESSA Pharma Inc.
[EPIX]
US$479 MM MCap
1Q20 IND submission for lead asset, EPI-7386, a small molecule targeting n-terminal domain of androgen receptor for mCRPC. First patient dosed in EPI-7386 Phase 1 study in mCRPC patients failing second generation antiandrogens by 2Q20. [more information]

Exicure
[XCUR]
US$194 MM MCap
Cavrotolimod (AST-008) in Ph2 trials for patients with Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma, with Ph1b data presented at AACR 2020. XCUR-FXN in preclinical development for patients with Friedreich's Ataxia, using genetically targeted SNA therapies to remove FXN transcription blockage. [more information]

Faraday Pharmaceuticals
Chronic and acute agents to prevent cardiac and skeletal muscle loss by modulating neurohumoral pathways and restoring metabolic flexibility: lead candidate FDY-5301 Ph 3 ready for reperfusion injury following heart attack (AMI). $57M raised to date from Arch Venture Partners, Polaris Partners, WRF, Osage [more information]

Galera Therapeutics
[GRTX]
US$253 MM MCap
Clinical stage biopharmaceutical company focusing on transforming radiotherapy in cancer. Lead asset GC4419 is a potent, highly selective small molecule dismutase mimetic being developed for severe oral mucositis, currently in Phase 3 with Breakthrough Therapy Designation. Topline results expected in 1H21. Top line results in Phase 1b/2a in second asset, GC4419 in pancreatic cancer expected in 2H20. GC4419 expected to initiate in Phase 1b/2a in lung cancer in 2H20. [more information]

Genfit SA
[GNFTF]
US$199 MM MCap
Development of elafibranor in PBC: ongoing enrollment for Ph 3 clinical trial ELATIVE™. Commercialization of NIS4™ for NASH diagnosis. [more information]

Geron Corporation
[GERN]
US$534 MM MCap
First-in-class telomerase inhibitor, imetelstat. Compelling Phase 2 data supports two ongoing Phase 3 clinical trials – one in lower risk MDS and the other in refractory MF. Highly experienced development team with previous imetelstat clinical and regulatory experience and cash resources expected to be sufficient to fund operations through the end of 2022. [more information]

HaemaLogiX
Proprietary, differentiated B cell targets engaged via antibody and CAR-T programs
KappaMab & LambdaMab target activated plasma cell antigens (KMA/LMA); KappaMab plus RevDex vs. RevDex Ph 2b in MM, data 1H20; Kappa CAR-T Ph 1 Q120 in MM; Capacity for dual-targeting via CD-19, BCMA, etc; LambdaMab in preclinical for amyloidosis [more information]

Hangzhou Chance Pharmaceuticals
Chance focuses on inhalation products with proprietary technologies. [more information]

Heidelberg Pharma AG
[HPHA:DB]
€179 MM MCap
Heidelberg Pharma AG (HPHA, Frankfurt Stock Exchange), based in Ladenburg, Germany, is a leading biotech company pioneering the use of its ATAC (Antibody Targeted Amanitin Conjugate) platform to develop novel cancer treatments with a unique mode of action effective at specifically killing both inactive and dividing cancers cells and overcoming tumor resistance mechanisms. [more information]

Humanigen Inc.
[HGEN]
US$1,033 MM MCap
Humanigen is developing Lenzilumab, an anti-GM-CSF therapy. Multiple ongoing trials for the treatment of COVID-related ARDS including the ACTIV-5 trial conducted by the NIH. Lenz originally developed to stop cytokine storm in CAR-T patients. [more information]

Immatics NV
[IMTX]
US$650 MM MCap
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer. [more information]

Impact Therapeutics Inc
Impact Therapeutics is a privately held clinical-stage biopharmaceutical company and dedicates to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. [more information]

IN8bio, Inc.
IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for both of its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma, which is a difficult to treat brain tumor that progresses rapidly, and INB-100 for the treatment of patients with acute leukemia undergoing hematopoietic stem cell transplantation. [more information]

Inozyme Pharma
[INZY]
US$589 MM MCap
Lead candidate INZ-701 is an enzyme replacement therapy designed to treat calcification disorders of the circulatory system, bone and kidney for which insufficient treatment options currently exist. ENPP1 and ABCC6 deficiency Phase 1/2 initiations expected H1'2021 with results H2'2021. [more information]

Invetx
Invetx is building the world’s premier biotechnology platform for protein-based therapeutics in animal health to transform standards of care in veterinary medicine. The Invetx team of highly experienced R&D leaders from both human biotech and animal health is supported by best-in-class biotechnology partners and an extensive network of industry experts, veterinary scientists and clinicians. Invetx is a private company headquartered in Boston, Massachusetts. [more information]

Iovance Biotherapeutics
[IOVA]
US$6,544 MM MCap
Late-stage cell therapy company utilizing proprietary autologous tumor infiltrating lymphocytes (TILs) to attack solid tumors. The company is conducting pivotal stage trials in metastatic melanoma and advanced cervical cancer with BLAs expected 2020. [more information]

ISA Pharmaceuticals BV
is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The Company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP®) concept and AMPLIVANT®technology. [more information]

Junshi Biosciences
[1877:HK]
Has a diversified R&D pipeline comprising 21 drug candidates with therapeutic areas covering cancer, metabolic, autoimmune, neurological, and infectious diseases. Product types include monoclonal antibodies, fusion proteins, antibody-drug conjugates, and small molecule drugs. With a combined 33,000L fermentation capacity in two GMP-facilities at Shanghai and Suzhou. JS001, or toripalimab, is approved by the NMPA and the first marketed anti-PD-1 mAb antibody self-developed by a PRC company. [more information]

Kadmon Holdings, Inc.
[KDMN]
US$904 MM MCap
Announced pos. primary analysis results (May 2020) in pivotal trial of ROCK inhibitor-KD025 (Belumosudil) in cGVHD pts receiving 2+ prior therapy lines; ORRs of 73% and 74% in 200mg QD and 200mg BID arms, respectively. Belumosudil is being reviewed under Real-Time Oncology Review (RTOR) Pilot Program by the FDA; NDA submission exp Q4 2020. Enrolling pts in Ph 2 trial (sys. sclerosis). [more information]

KAHR
The company lead product, DSP107, is a CD47-41BB targeting compound that simultaneously target cancer cells, weaken their innate defenses and activate an effective, local response of both innate (by blocking ‘Don’t eat me’ signals) and adaptive immunity (by providing co-stimulation signal to T and NK cells). [more information]

Kaleido BioSciences
[KLDO]
US$454 MM MCap
Harnessing proprietary small molecule chemistry platform to develop microbiome metabolic therapies (MMT) in indications spanning I-O, nitrogen metabolism, metabolic diseases, and CNS. Topline data expected in 1Q21 from multi-center (K031) clinical study of KB109 in outpatients with mild-to-moderate COVID-19 disease and from study with Massachusetts General Hospital (K032). Topline data from clinical study of KB295 in approximately 30 patients with mild-to-moderate UC expected mid-2021, topline data from UNL [more information]

Keros Therapeutics
[KROS]
US$1,543 MM MCap
Our lead protein therapeutic product candidate, KER-050, is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and myelofibrosis. [more information]

Kineta Inc.
Kineta (Private) - wholly owned preclinical anti-VISTA (innate immune target) antibody reprograms the tumor microenvironment and is differentiated from other immunotherapies by blocking suppressive cells in cold tumors. $360M+ deal with Genentech for KCP506, Ph1 non-opioid for chronic pain. [more information]

Kintor Pharma
[9939-hk]
Two Ph3s ongoing in China: Pivotal monotherapy and combo with abiraterone and a Ph2 ongoing in US for mCRPC (with breast and other AR-driven cancers behind). Additional pipeline includes a topical AR for alopecia and earlier-stage targets including ALK-1 and hedgehog. [more information]

Landos Biopharma
Based on extensive preclinical studies, Landos has validated a unique mechanism of action involving LANCL2 that exerts potent anti-inflammatory effects with an outstanding safety profile. Lead asset BT-11 Phase 2 interim read out in mid-2020 in UC. [more information]

LianBio
LianBio collaborates with world-class partners across a diverse array of therapeutic and geographic areas to build out a pipeline based on disease relevance and the ability to impact patients with transformative mechanisms and precision-based therapeutics. [more information]

Lineage Cell Therapeutics Inc.
[LCTX]
US$372 MM MCap
Cell therapy company with 3 clnical programs 1) OpRegen, an RPE transplant therapy in Ph1/2a development for the treatment of dry-AMD. 2) OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries with Orphan and RMAT designations. 3) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in a Ph 1 for NSCLC conducted by CRUK. [more information]

Marker Therapeutics
[MRKR]
US$92 MM MCap
A clinical-stage immuno-oncology company with the potential to significantly disrupt the current cell therapy landscape. Marker's current MultiTAA cell therapy is looking to initiate a Phase II study in AML in 2020 with enrollment completion anticipated in 2H20. The company also has a T-cell vaccine program, currently being studied in breast cancer. [more information]

Maxcyte
[MXCT:LN]
global cell therapy company providing proprietary non-viral cell engineering technology for the next generation of cell-based therapies including gene editing and immuno-oncology. MaxCyte may be seen as a play on the cell therapy market with its blue chip client base. [more information]

MEI Pharma, Inc.
[MEIP]
US$341 MM MCap
Broadening zandelisib development activity includes addition of marginal zone lymphoma arm to TIDAL to support expansion of an accelerated approval strategy if successful, the initiation of a Phase 3 study in second line follicular and marginal zone lymphomas in mid-2021, and plans to support select investigator-initiated trials, initially in first-line DLBCL. [more information]

Merus NV
[MRUS]
US$1,082 MM MCap
Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. [more information]

Minoryx Therapeutics
Oral PPARg agonist, MIN-102, in Pivotal Ph 2/3 for X-linked ALD and Ph 2 Friedrich’s Ataxia; data for both expected by end of 2020. VC investors include Kurma, Ysios, Fund+, Roche, Idinvest, etc
[more information]

Monte Rosa Therapeutics
Next-generation molecular glue-based targeted protein degradation platform developing small molecule therapeutics that selectively degrade disease-causing proteins. Targeting the undruggable proteome in oncology and non-oncology indications via AI based degron prediction. Extensive in vivo data to date has demonstrated potent anti-tumor activity. Lead program focused on GSPT1, a key regulator and vulnerability of Myc-induced translational addiction. DC selection for lead program expected in 2021. [more information]

Nanobiotix SA
[NBTX]
US$601 MM MCap
Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell. Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies. [more information]

Neoleukin Therapeutics
[NLTX]
US$564 MM MCap
Lead program NL-201: is a dual-acting IL-2 and IL-15 agonist immunotherapy for cancer, designed to improve tolerability and activity by eliminating the alpha receptor binding interface (IND completed 4Q20). First de novo protein therapeutic ever created. [more information]

NeuroRx
Leading Relief Therapeutics Ph 2 trial of Aviptadil to treat COVID-19 induced ARDS in the US. In Phase 3 with readout expected mid-January 2021. Also developing first Glx targeted antidepressant to address suicidality in bipolar depression. NRX-101 is in Ph 2b/3 development, (Breakthrough Designation, SPA and Fast Track Designation by FDA) for Severe Bipolar Depression in pts w Acute Suicidal Ideation and Behavior. [more information]

NexImmune, Inc.
Multi-antigen-specific T cell therapy. Synthetic nanoparticles decorated w a combo of multiple tumor relevant antigens and co-stimulatory signals engaging directly w targeted T cells. Two Ph 1's ongoing. [more information]

NorthSea Therapeutics
First-in class, oral, structurally engineered fatty acids [SEFAs] addressing NASH and associated metabolic disorders via unique targeting of pathways regulating metabolism, oxidative stress, inflammation, and fibrosis. $40m Series B (Jan 2020) with venBio Partners (lead) and Sofinnova Investments. [more information]

Oncopeptides AB
[ONCO:ST]
SKr10,768 MM MCap
Potential approval for Melflufen (Ygalo) 1Q21. First in class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells. H2H versus Pomalyst completed enrollment Sep '20. [more information]

OncoResponse
The company's technology leverages the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of antibody-derived therapeutics for the treatment of cancer, providing a larger number of cancer patients with the benefit of immunotherapy. [more information]

Oncorus
[ONCR]
US$527 MM MCap
Oncorus is the leader in next-generation oncolytic immunotherapies. The company's lead program is a Ph1 oHSV with complementary payloads to encourage immune stimulation (PD1, CCL4, IL12, FLT3, CTLA4). Secondary programs include synthetic viruses that do not need to be dosed intra-tumorally. [more information]

OnKure Therapeutics, Inc.
Developing epigenetic cancer therapies including HDAC inhibitors. Lead asset OKI-179 is a class 1 HDAC inhibitor in Ph 1. [more information]

PharmaMar SA
[PHM:ES]
Revenue generating with marine-derived and novel MoA oncology products. Yondelis (soft tissue sarcoma and ovarian cancer) commercialized with direct sales-force in EU and partnership in US with Janssen. Signed licensing agreement with Jazz Pharma for lurbinectedin in the US - upfront payment of $200M, $100mm on approval and up to $550M sales milestones. [more information]

Pharming Group NV
[PHARM:AS]
€752 MM MCap
recent in-license from Novartis of late stage drug Leniolisib for APDS (ultra-rare immunodeficiency condition), rhC1INH for new larger indications including COVID-19, pre-eclampsia, AKI and additional pipeline product from technology platform: recombinant alpha-Glucosidase for Pompe disease. [more information]

Photocure ASA
[PHO:OS]
NKr2,734 MM MCap
Photocure is a revenue-generating commercial stage company focused on urology. Lead product Hexvix/Cysview is an optical imaging agent for improved detection, reduced disease recurrence and progression rates of bladder cancer. [more information]

Pliant Therapeutics, Inc.
[PLRX]
US$967 MM MCap
Focused on discovering and developing therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that is in development for the treatment of idiopathic pulmonary fibrosis, and primary sclerosing cholangitis. Second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with NASH, which Pliant has partnered with Novartis. [more information]

PROSION
A pharmaceutical drug discovery company with proline derived modules (ProMs) as the world’s first PRM structure mimicking building blocks. The company develops a new class of drugs and is able to address yet undruggable considered targets that are related to various indications. For its first of many use-cases, PROSION has already shown a remarkable in vivo effect of its ProM-based anti-metastatic inhibitor – both in pancreatic and breast cancer xenograft rodent models. [more information]

Protagonist Therapeutics
[PTGX]
US$889 MM MCap
Proprietary peptide technology platform to develop oral targeted therapy-based drugs and injectables for rare diseases. PTG-300 injectable hepcidin mimetic Ph 2 trials ongoing in polycythemia vera and hereditary hemochromatosis; positive updated Ph 2 results in PV presented at ASH 2020. PN-943 oral GI-restricted alpha-4-beta-7 antagonist Ph 2 in ulcerative colitis study sites activated; PTG-200, partnered w/ Janssen, oral GI-restricted IL-23R antagonist Ph 2 Crohn’s disease study ongoing. [more information]

R2 Technologies
Headquartered in Silicon Valley, R2 focuses on the development and commercialization of groundbreaking technologies for aesthetic providers and consumers. Based on the licensed exclusive intellectual property from Massachusetts General Hospital to modulate melanin production, R2 Technologies was founded in 2014 by Pansend Life Sciences and Blossom Innovations. [more information]

Rigel Pharmaceuticals
[RIGL]
US$598 MM MCap
Focused on inhibiting pathways related to immune-mediated and inflammatory disease. In April 2018, Rigel launched its first commercial product, TAVALISSE (fostamatinib) into a $1 billion US market for immune thrombocytopenia (ITP), a rare hematological disorder. TAVALISSE is also in a pivotal Phase 3 trial for an warm autoimmune hemolytic anemia (wAIHA), a hematologic disorder with no FDA-approved therapy. [more information]

Ryvu Therapeutics
[RVU:WAR]
Potential first in class CDK8 inhibitor for leukemias, lymphomas, and solid tumors in Ph1b in AML and high-risk MDS, PIM/FLT3 kinase inhibitor in Ph 1/2 in AML (partnered w Menarini). Data in 2020. Early stage pipeline addressing emerging solid tumor targets. [more information]

Savara Inc.
[SVRA]
US$97 MM MCap
Orphan lung disease Company; Molgradex, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP); study expected to start Q1 2021. Also, Phase 3 trial, AVAIL, is evaluating persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in people living with cystic fibrosis. Top line data are expected early in 2021 [more information]

Secarna Pharmaceuticals GmbH
Secarna's uniquely efficient LNAplus™ discovery process is fueled by their proprietary and streamlined Oligofyer™ bioinformatics systems large in-house cell library and own in vitro screening assays. [more information]

Sol-Gel Technologies Ltd.
[SLGL]
US$239 MM MCap
Commercializing branded generic topical drug products (skin diseases). Two positive Phase 3 programs, both with PDUFA dates in 2021: Epsolay has potential to be first FDA-approved single-agent benzoyl peroxide prescription drug product for rosacea (PDUFA date on April 26th). Twyneo has potential to be the first acne treatment that contains fixed dose combination of BPO and tretinoin (PDUFA date on August 1st). [more information]

Sonnet Biotherapeutics, Inc.
[SONN]
US$49 MM MCap
Sonnet's interleukin-based candidate has been shown to enhance pK (up to 10 fold) and improve tumor delivery with an increase in in vivo efficacy (30 fold) as demonstrated in a mice tumor model. The Sonnet platform de-risks the use of interleukins by greatly extending their in vivo half-life, while also improving their specificity to tumor tissue. [more information]

Spruce Biosciences
[SPRB]
US$487 MM MCap
The company’s lead product candidate, tildacerfont, is an investigational oral drug that is being evaluated in studies for the treatment of congenital adrenal hyperplasia (CAH). The company also plans to evaluate tildacerfont in other diseases impacted by elevated ACTH or adrenal androgens. [more information]

sterna biologicals
By targeting transcription factors that play a central role in regulating Th1- and Th2-driven inflammatory mechanisms, the Company’s proprietary DNAzyme-based drug candidates can intervene with upstream inflammatory processes to address related diseases more effectively. Sterna currently has four programs in phase 2 development. [more information]

Strongbridge Biopharma
[SBBP]
US$191 MM MCap
Rare diseases; Keveyis for PPP revs ~21.7M for 2019 and $26 - $27M for 2020. Recorlev for endogenous Cushing's syndrome Ph 3 published with topline placebo-controlled Ph 3 3Q20. [more information]

Sutro Biopharma
[STRO]
US$996 MM MCap
FolRα-targeting ADC (STRO-002) Phase 1, additional dose escalation data in 4Q20. CD74-targeting ADC (STRO-001) Phase 1, additional dose escalation data in 4Q20. BMS collaboration Phase 1 clinical development update for CC-99712 (BCMA-targeting ADC). Merck collaboration update in 2020 on first cytokine derivative program. [more information]

Syneos Health
[SYNH]
US$7,840 MM MCap
Syneos Health® is an end-to-end, fully integrated biopharmaceutical solutions company that works differently. At Syneos Health, all the disciplines involved in bringing new therapies to market, from clinical to commercial, work together to create customer success. Our unique Biopharmaceutical Acceleration Model delivers value across the small to mid-size to large customer continuum. [more information]

Teon Therapeutics
Pipeline of next-generation cancer therapeutics targeting GPCRs including a highly-specific A2B antagonist and EP4 antagonist, both slated to enter Phase 1b trials in 2021. [more information]

Utility Therapeutics
UTILITY has received the FDA’s QDIP (qualified infectious disease product) designation for both products and plans to file an NDA in 2021 for pivemecillinam for the treatment of uncomplicated UTIs. Pivmecillinam is currently recommended as a first-line therapy in the current IDSA (Infectious Disease Society of America) treatment guidelines for uncomplicated UTIs. [more information]

Vaccitech Limited
Proprietary ChAdOx (prime) and MVA (boost) technology platform induces and maintains CD8+ T-cells at the maximum levels published to date. Ph1/2 data for HPV and HBV immunotherapies expected 2H20. Encouraging prostate cancer, 5T4 immunotherapeutic data recently released. Ph1/2 NSCLC MAGE-NYESO immunotherapeutic enters clinic in Q1 2021. ChAdOx COVID-19 vaccine out-licensed to Oxford Uni/AstraZeneca with post-pandemic revenue stream. $150M funding at Jenner Institute and company raised $48M since formation [more information]

Vericel Corporation
[VCEL]
US$1,856 MM MCap
Advanced cell therapy; marketing MACI (cartilage repair) and Epicel (skin replacement) in TAMs of $2b+. Q3 MACI and Epicel revs of $31.1m. Reported record third quarter MACI revenue and total revenues, and the second highest quarterly Epicel revenue in history. NexoBrid PDUFA date of June 29, 2021. [more information]

Verrica Pharmaceuticals
[VRCA]
US$299 MM MCap
Verrica Pharmaceuticals is a dermatology therapeutics company developing medications for viral skin diseases requiring medical attention. Lead product, VP-102 for molluscum contagiosum has a PDUFA date of July 13, 2020. Phase 2 data in external genital warts expected in 2H20. Initiation of Phase 3 in common warts in 1H20 and initiation of Phase 2 in plantar warts in mid-2020. [more information]

Viela Bio
[VIE]
US$1,958 MM MCap
UPLINZA® (inebilizumab, anti-CD19 mAb) on the market for the treatment of neuromyelitis optica spectrum disorder (NMOSD). Additional trials with inebilizumab ongoing, including Ph 3 trials in myasthenia gravis and IgG4-related disease. VIB7734, anti-ILT7 mAb, Ph 2 trial to initiate in 1H21. Ph 2 trials ongoing for VIB4920 (Anti-CD40L-Tn3 Fusion Protein) in Sjogren's Syndrome and kidney transplant rejection. [more information]

XOMA Corporation
[XOMA]
US$424 MM MCap
Biotech royalty and milestone aggregator with portfolio of 65+ assets in >30 disclosed indications where R&D costs are borne by partners e.g. Novartis’s Iscalimab (CFZ533) anti-CD40 mAb in Ph2. [more information]

Zentalis
[ZNTL]
US$1,778 MM MCap
Discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective estrogen receptor degrader for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor and ZN-e4, an EGFR inhibitor. [more information]